Approval · Notice of Compliance 12825 · 2011
SALOFALK: Notice of Compliance 12825
Issued December 1, 2011
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 12825
- Date
- December 1, 2011
- Company
- Aptalis Pharma Canada UlcMarkham, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Manufacturer Name Change
- Therapeutic class
- Lower Gastroinestinal Trant Anti-inflammatory
Products in this notice
Medicinal ingredients
- MESALAZINE 2 G per 60G
- MESALAZINE 4 G per 60G
- MESALAZINE 500 MG per TAB
- MESALAZINE 500 MG per SUP
- MESALAZINE 1,000 MG per SUP